Triple-Negative Breast Carcinoma — Trials

Triple-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 417
Recruiting: 234
Ph III recruiting: 22
Growth YoY: +2.4%
Industry share: 31%
Top sponsor: Fudan University
Termination share: 47.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 51–52 of 52 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02641847	TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature	active not recruiting	Phase 2 / Phase 3	503	Fudan UniversityOTHER	1	Jan 25, 2024	clinicaltrials
NCT02315196	Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer	active not recruiting	Phase 2	62	Rutgers, The State University of New JerseyOTHER	1	Mar 29, 2023